These medications belong to a class of drugs called GLP-1 receptor agonists, which help manage blood sugar and support weight loss
The anti-inflammatory pathways modulated by GLP-1 receptor activation (NF-kB suppression, macrophage polarization, Treg enhancement) are largely distinct from the pathways targeted by: Methotrexate: Folate metabolism disruption, different anti-inflammatory pathway TNF inhibitors (adalimumab, etanercept): Direct TNF blockade, whereas GLP-1 reduces TNF production upstream IL-6 inhibitors (tocilizumab): Receptor-level blockade, while GLP-1 reduces IL-6 production JAK inhibitors (tofacitinib, baricitinib): Different signaling pathway entirely Corticosteroids: Broad immunosuppression, while GLP-1 is immunomodulatory This pathway complementarity is why additive benefit is biologically plausible
c-Met: structure, functions and potential for therapeutic inhibition
Using a cut-off value of 10.0 ng/ml, NRF2-MS showed 42% sensitivity and 48% specificity, with positive and negative predictive values of 45% and 46%, respectively
